PD-L1/TLR7 Dual-Targeting Nanobody-Drug Conjugate Mediates Potent Tumor Regression Via Elevating Tumor Immunogenicity in a Host-Expressed PD-L1 Bias-Dependent Way.
Journal for immunotherapy of cancer（2022）
Key words
PD-L1,TLR7,nanobody-drug-conjugate,cancer immunotherapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined